Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hetero Drugs Ltd.

http://www.heterodrugs.com

Latest From Hetero Drugs Ltd.

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Strategy Sales & Earnings

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Commercial Sales & Earnings

Coronavirus Update: Gilead And Zydus Cadila Expand Drugs Available In India

Gilead outlines efforts to expand availability of remdesivir in India while offers for supplies from Russia, Uzbekistan are also on the table. Zydus Cadila has received accelerated approval in India for pegylated interferon alpha-2b in moderate COVID-19 infection in adults.

Commercial Coronavirus COVID-19

MSD Licenses Molnupiravir In India

MSD India outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.

Deals Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register